Prostate cancer: F-18-fluorocholine PET-CT utility. [Cancer de la prostate : utilité de la TEP-TDM à la 18F-fluorocholine.]

Détails

ID Serval
serval:BIB_F25EE3596E91
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Prostate cancer: F-18-fluorocholine PET-CT utility. [Cancer de la prostate : utilité de la TEP-TDM à la 18F-fluorocholine.]
Périodique
Médecine Nucléaire
Auteur(s)
Boubaker A., Houzard C., Zouhair A., Got P., Orcurto M.V., Giammarile F.
ISSN
0928-1258
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
35
Numéro
8
Pages
446-454
Langue
français
Résumé
In oncology, positron emission computed tomography (PET/CT) has become an essential tool for initial staging, response evaluation and follow-up of cancer patients. Most of the frequent tumors (lung, breast, esophagus, and lymphomas) are highly avid for (18)F-fluorodeoxyglucose ((18)FDG), but prostate cancer has not demonstrated significant uptake of FDG. The development of new tracers labeled with (18)F such as choline analogs allowed already to obtain interesting results particularly in patients with biological relapse and inconclusive conventional imaging workup. The impact of (18)F-flurocholine PET/CT on patient management needs to be validated in large studies, but many centers use already this examination in order to guide further management, including radiotherapy planning. (C) 2011 Elsevier Masson SAS. All rights reserved.
Mots-clé
Fluorocholine, Prostate cancer, PET, Imaging, POSITRON-EMISSION-TOMOGRAPHY, F-18 FLUOROCHOLINE, LOCALIZATION
Web of science
Création de la notice
29/09/2011 10:31
Dernière modification de la notice
03/03/2018 22:40
Données d'usage